(UPDATED) A fully human monoclonal antibody that specifically targets inflammation reduces the risk of cardiovascular events when added to a background of optimal medical therapy, a new study has ...

Patients with prior MI and elevated high-sensitivity C-reactive protein (hsCRP) see a dose-dependent reduction in heart-failure hospitalization while taking the anti-inflammatory drug canakinumab ...

Hard tech is hard, but when there are major breakthroughs, that can come with outsize returns and enormous opportunities. Cantos just closed its third fund to invest in science-forward companies at ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Among adults with atherosclerotic CVD and impaired kidney function, residual inflammation is a ...

BARCELONA, SPAIN — The anti-inflammatory drug canakinumab (Ilaris, Novartis) significantly decreased the risk of recurrent major CV events without any effect on cholesterol and, in a surprising twist, ...